WHO ICTRP trial
Treating obsessive-compulsive disorder in patients with Bipolar disorder
IRCT20200614047761N1 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20200614047761N1 |
|---|---|
| Public title | Treating obsessive-compulsive disorder in patients with Bipolar disorder |
| Scientific title | Comparison Aripiprazole & Risperidone effectiveness in treating obsessive-compulsive disorder in patients with Bipolar disorder |
| Primary sponsor | Babol University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Condition 1: Bipolar disorder. Condition 2: Obsessive-Compulsive disorder. Bipolar disorder Obsessive-compulsive disorder |
| Interventions | Intervention 1: Intervention group: Aripiprazole (Sobhan Company) Begins with an initial dose of 2.5 mg per day and gradually increased to a dose of 5 to 20 mg per day. Intervention 2: Intervention group: Raspidron (Porsina)Begins with an… |
| Registration date | Jun 18, 2020 |
| Target size | 60 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: